Cite
MLA Citation
K. Yamazaki et al.. “365 Identification of the recommended phase II dose (RP2D) of the c-Met Inhibitor tepotinib (MSC2156119J) in Japanese patients (pts) with solid tumors: A phase I trial.” European journal of cancer, vol. 51, n.d., pp. S75–S76. http://access.bl.uk/ark:/81055/vdc_100030628020.0x000044